Spruce Biosciences (SPRBD) Stock Price, News & Analysis

Company Overview

Spruce Biosciences, Inc. is a clinical-stage specialty biopharmaceutical company focused on developing targeted therapies for rare endocrine diseases. The company’s research strategy centers on modulating the hormonal axis to address underlying disease mechanisms rather than treating symptoms alone. By concentrating on orphan indications with high unmet medical need, Spruce aims to deliver novel treatment options for patients who have limited alternatives under current standard-of-care regimens.

Spruce’s lead product candidate is tildacerfont, an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist in development for adults with classic congenital adrenal hyperplasia (CAH). The company is also advancing relacorilant, a selective glucocorticoid receptor modulator licensed from Corcept Therapeutics, for use in endogenous Cushing’s syndrome. Both programs have progressed through Phase 2 clinical trials, demonstrating favorable safety profiles and biomarker responses that support further study in pivotal trials.

Founded in 2019 and headquartered in Redwood City, California, Spruce Biosciences operates a compact research and development infrastructure in the San Francisco Bay Area. The company is led by President and Chief Executive Officer Megan O’Connor, whose leadership team combines expertise in endocrinology, drug development and commercialization. With its pipeline poised for late-stage development, Spruce is preparing for potential regulatory filings and global partnerships to extend its therapies to patient populations worldwide.

Key Stats

• Today's Range: $8.32 to $12.75
• 50-Day Range: $7.00 to $12.40
• 52-Week Range: $4.28 to $45.60
• Volume: 75,838 shs
• Average Volume: 9,786 shs
• Market Capitalization: $6.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SPRBD Stock Analysis - Frequently Asked Questions

How have SPRBD shares performed this year?

Spruce Biosciences' stock was trading at $9.01 on January 1st, 2025. Since then, SPRBD stock has increased by 37.6% and is now trading at $12.40.

How do I buy shares of Spruce Biosciences?

Shares of SPRBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTC
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTC:SPRBD
• Previous Symbol: OTC:SPRBD
• CIK: 1683553
• Web: www.sprucebiosciences.com
• Phone: (650) 600-2400
• Fax: N/A
• Employees: N/A
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 562,000
• Free Float: N/A
• Market Cap: $6.97 million
• Optionable: N/A
• Beta: 2.43